GlassScriptPhysician profile
Craig Michael Coleman
NPI 1154841617
$4,288.84
in general payments reported to CMS, 2019-2025
37 companies · $881 in 2025
The $881 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $186 · 2021: $577 · 2022: $831 · 2023: $693 · 2024: $1,121 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.30 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $688.11 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.08 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $374.63 | 2020-2025 | Verquvo, Gardasil 9, Steglatro |
| Amgen INC. | $350.54 | 2020-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $305.30 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $208.48 | 2021-2024 | Injectafer |
| Abbott Laboratories | $185.06 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $171.22 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $160.63 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $154.50 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Abbvie INC. | $145.64 | 2022-2025 | Synthroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.06 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $89.60 | 2021 | |
| Currax Pharmaceuticals LLC | $83.09 | 2022-2023 | Nexletol, Contrave |
| Pfizer INC. | $72.56 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.